Aspira Women's Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass

Stock Information for Augmedix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Augmedix Inc.

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub
Aspira Women's Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
Aspira Women's Health Reports Second Quarter 2024 Financial Results
Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference
Aspira Women's Health Announces Poster Presentation at the Menopause Society's 2024 Annual Meeting
Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.